Any other matters that need to be specified:
(1)Name of the new drug: Active immunotherapeutic agent, Adagloxad Simolenin (OBI-822)
(2)Uses: OBI-822 is an active immunotherapeutic agent targeting Globo H. Globo H conjugated with KLH, a carrier protein, can trigger the production of anti-Globo H antibodies. The immune response can be used to treat cancer. https://www.clinicaltrials.gov/ct2/show/NCT03562637?cond=OBI-822&rank=1
(3)Planned development: Phase III clinical trial and NDA
(4)Ongoing development:
A.Filed application/ Granted/ Denied: granted
B.Risk and countermeasures for denied applications: N/A
C.Outlook for granted applications: Phase III Clinical Trial
D.Total invested capital: To be kept confidential to avoid complications in future negotiation of licensing deals, and as for the best interest of shareholders.
(5)Next phase of development:
A.Expected timeline: expect to evaluate the primary endpoint by 2023. The actual study timeline will be based on the progress of the clinical trial.
B.Expected obligation: Upon initiation of Phase III clinical trial, milestone royalty of US$500,000 and US$1,000,000 to MSKCC and Optimer, respectively.
(6)Current market: According to EvaluatePharma, the global market for anti-tumor drugs is about US$100.9 billion in 2017, the largest among the top 10 categories.
However, OBI-822 is still in the clinical phase. The development of indications is based on the unmet medical needs where future development of the drug will be determined after a comprehensive consideration of the company’s overall product pipeline and strategy.
(7)New drug development is a long process associated with high costs. It is not a guaranteed success, which may increase the risk of investment. Investors shall make prudent judgments and investments.